Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Rugo Spotlights Potential With Tucatinib, Other Novel Agents in HER2+ Breast Cancer

March 7th 2020

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

All Stakeholders Are Responsible for Genetic Testing

March 7th 2020

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

Immunotherapy Comes of Age in Breast Cancer

March 7th 2020

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

Dr. Hughes on Genetic Testing in Breast Cancer

March 7th 2020

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.

Gene Profiling Essential Tool for Treatment Tailoring

March 7th 2020

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

March 6th 2020

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Can We Use Genomic Profiling Data to Influence Locoregional Treatment Decisions in Breast Cancer?

March 6th 2020

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast Cancer

March 5th 2020

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

NEJM Data Highlight Neoadjuvant Pembrolizumab Benefit in TNBC

March 3rd 2020

The neoadjuvant combination of pembrolizumab plus chemotherapy led to a higher pathological complete response rate compared with placebo/chemotherapy in patients with early triple-negative breast cancer, across various patient subgroups.

Dr. Wright on Key Strategies in Using Radiation in Breast Cancer Treatment

March 3rd 2020

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

Key Questions Surround CDK4/6 Inhibitors in HR+ Breast Cancer

February 28th 2020

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.

Breast Oncologists Aim to Address Key Unanswered Questions With Novel Research Efforts

February 26th 2020

Experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.

Nodal Involvement Impacts Surgical Management of Axilla in Breast Cancer

February 19th 2020

Hernan Vargas, MD, FACS, discusses the criteria that are used to determine the appropriate surgical intervention for patients with node-positive breast cancer and shared questions that still need to be addressed in the space.

Tailored RT Approaches Poised to Alter Treatment in Early-Stage Breast Cancer

February 18th 2020

Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.

Dr. Hamilton on the Results of the KATHERINE Trial in HER2+ Breast Cancer

February 14th 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

Frontline Pembrolizumab/Chemo Combo Improves PFS in PD-L1+ Metastatic TNBC

February 12th 2020

The frontline combination of pembrolizumab and chemotherapy significantly improved progression-free survival compared with chemotherapy alone in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

February 12th 2020

Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1

NewYork-Presbyterian/Columbia University Breast Cancer Faculty Share 2020 Resolutions to Improve Patient Care

February 7th 2020

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer

February 7th 2020

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Dr. Neven on the Design of the MONALEESA-3 Trial in Advanced Breast Cancer

February 7th 2020

Patrick Neven, MD, outlines the design of the phase III MONALEESA-3 trial in hormone receptor–positive, HER2-negative advanced breast cancer.